If POC1 launches without ADO, it will be ugly. If this happens, the market probably won't look far enough to consider the potential for inclusion in subsequent release and new assays.
Blink and you'll miss it... there appears to be only one reference to POC1 in the quarterly, written in the summary near the end of the report.
"Our ongoing interactions, including those with PoC1, have continued to progress pleasingly through the quarter. Product development activities have opened up new avenues to explore with both new and interested parties.”
No mention of BBI.
News to sell on, page-78
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(3.67%) |
Mkt cap ! $52.28M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.3¢ | 2.1¢ | $7.812K | 349.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 828094 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1102151 | 4 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ADO (ASX) Chart |